title: Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia.
authors.forename: P P
authors.initials: PP
authors.lastname: Piccaluga
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: M
authors.initials: M
authors.lastname: Malagola
authors.forename: M
authors.initials: M
authors.lastname: Rondoni
authors.forename: F
authors.initials: F
authors.lastname: Bonifazi
authors.forename: G
authors.initials: G
authors.lastname: Bandini
authors.forename: G
authors.initials: G
authors.lastname: Visani
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004921:Erythropoietin / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D000074323:Alemtuzumab